ASS1 and glioblastoma: In 2019, a phase I study on ASS1-deficient recurrent and highly pretreated high-grade glioblastoma multiforme (GBM) patients confirmed safety and induction of stable disease in 80% of patients receiving a PEG-ADI [10].